New Two-in-One cancer drug enters human testing

NCT ID NCT07274813

Recruiting now Disease control Sponsor: Shanghai Henlius Biotech Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests HLX37, a new drug that targets two cancer growth pathways (PD-L1 and VEGF) at once, in people with advanced solid tumors that have spread. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Up to 254 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HLX37 (a bispecific antibody that targets PD-L1 and VEGF)
What this could lead to: If successful, this could lead to a new treatment option for advanced solid tumors by blocking two cancer pathways at once.
What could go wrong: This is a very early (Phase 1) trial focused on safety and dosing, so it's too soon to know if HLX37 will be effective. Side effects from targeting both PD-L1 and VEGF could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED/METASTATIC SOLID TUMORS NSCLC

Contacts and locations

Locations

Shanghai Chest Hospital
RECRUITING

Shanghai, China
The Second Affiliated Hospital of Air Force Medical University of the People's Liberation Army of China
RECRUITING

Xi'an, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.